Células CAR-T en Dermatología: mecanismos de acción y aplicaciones en enfermedades autoinmunes.

Saved in:

Bibliographic Details
Title:	Células CAR-T en Dermatología: mecanismos de acción y aplicaciones en enfermedades autoinmunes.
Alternate Title:	CAR-T cells in Dermatology: Mechanisms of action and applications in autoimmune diseases.
Authors:	Morales-Hernández, Osmara¹, Méndez-Flores, Silvia¹ silvia.mendezf@incmnsz.mx
Source:	Revista Medica del IMSS. mar/abr2025, Vol. 63 Issue 2, p1-7. 7p.
Subjects:	LUPUS erythematosus, AUTOIMMUNE diseases, PEMPHIGUS vulgaris, CLINICAL medicine, CHIMERIC antigen receptors
Abstract (English):	Chimeric Antigen Receptor T (CAR-T) cells have revolutionized the treatment of hematological malignancies and are expanding into autoimmune rheumatological diseases. In dermatology, they open a new therapeutic field for autoimmune disorders. The aim of this article is to evaluate the mechanisms of action and therapeutic applications of CAR-T cells in autoimmune dermatological diseases, exploring the challenges and future perspectives for their clinical application. A thorough review was conducted in PubMed of preclinical and clinical studies on the application of CAR-T in dermatological diseases, selecting articles from the last 5 years with a focus on autoimmune diseases. The potential of CAR-T cells in autoimmune dermatological diseases is highlighted, such as in pemphigus vulgaris, where CAR-T cells targeting pathogenic anti-Dsg3 B cells have shown efficacy. In cutaneous lupus erythematosus, CAR-T cells directed at CD19 have achieved significant clinical remissions. Additionally, applications in psoriasis and melanoma are explored, although efficacy is limited by adverse factors. CAR-T therapy represents a promising option for the management of refractory dermatological diseases, with favorable results in preclinical and clinical models. However, its clinical implementation faces challenges such as optimizing safety and reducing off-target effects. Future research should focus on next-generation CARs and clinical trials that validate their efficacy and safety profile in dermatology. [ABSTRACT FROM AUTHOR]
Abstract (Spanish):	Las células T con receptores de antígenos quiméricos (CAR-T) han revolucionado el tratamiento de las neoplasias hematológicas, además de expandirse a enfermedades autoinmunes reumatológicas. En Dermatología, abren un nuevo campo terapéutico para trastornos autoinmunes. El objetivo de este artículo es evaluar los mecanismos de acción y aplicaciones terapéuticas de las CAR-T en enfermedades dermatológicas autoinmunes, explorando desafíos y perspectivas futuras para su apliación clínica. Se realizó una revisión exhaustiva en PubMed de estudios preclínicos y clínicos sobre la aplicación de CAR-T en enfermedades dermatológicas, seleccionando artículos de los últimos 5 años con enfoque en patologías autoinmunes. Se destaca el potencial de las células CAR-T en enfermedades dermatológicas autoinmunes, como el pénfigo vulgar, en donde las CAR-T dirigidas contra las células B patógenas anti-Dsg3 han mostrado eficacia. En el lupus eritematoso cutáneo las CAR-T dirigidas a CD19 han logrado remisiones clínicas significativas. Además, se exploran aplicaciones en psoriasis y melanoma, aunque la eficacia está limitada por factores adversos. La terapia con células CAR-T representa una opción prometedora para el manejo de enfermedades dermatológicas refractarias, con resultados favorables en modelos preclínicos y clínicos. Sin embargo, su implementación clínica enfrenta desafíos, como la optimización de seguridad y la reducción de los efectos fuera del objetivo. La investigación futura deberá enfocarse en CARs de nueva generación y en ensayos clínicos que validen su perfil de eficacia y seguridad en Dermatología. [ABSTRACT FROM AUTHOR]
	Copyright of Revista Medica del IMSS is the property of Direccion de Prestaciones Medicas - IMSS and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	MedicLatina

Description
Abstract:	Chimeric Antigen Receptor T (CAR-T) cells have revolutionized the treatment of hematological malignancies and are expanding into autoimmune rheumatological diseases. In dermatology, they open a new therapeutic field for autoimmune disorders. The aim of this article is to evaluate the mechanisms of action and therapeutic applications of CAR-T cells in autoimmune dermatological diseases, exploring the challenges and future perspectives for their clinical application. A thorough review was conducted in PubMed of preclinical and clinical studies on the application of CAR-T in dermatological diseases, selecting articles from the last 5 years with a focus on autoimmune diseases. The potential of CAR-T cells in autoimmune dermatological diseases is highlighted, such as in pemphigus vulgaris, where CAR-T cells targeting pathogenic anti-Dsg3 B cells have shown efficacy. In cutaneous lupus erythematosus, CAR-T cells directed at CD19 have achieved significant clinical remissions. Additionally, applications in psoriasis and melanoma are explored, although efficacy is limited by adverse factors. CAR-T therapy represents a promising option for the management of refractory dermatological diseases, with favorable results in preclinical and clinical models. However, its clinical implementation faces challenges such as optimizing safety and reducing off-target effects. Future research should focus on next-generation CARs and clinical trials that validate their efficacy and safety profile in dermatology. [ABSTRACT FROM AUTHOR]
ISSN:	04435117
DOI:	10.5281/zenodo.14617135